New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.

Canada: A recent observational cohort study from Canada revealed that older diabetic patients taking GLP-1 receptor ...

Researchers have zeroed in on yet another possible ocular concern for diabetes patients who take popular GLP-1 therapies in a ...

Semaglutide, widely used to treat diabetes and obesity, was associated with more than double the risk of developing ...

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Intravitreal anti-vascular epithelial growth factor (VEGF) therapies provide significant anatomical and visual-acuity benefits to patients with neovascular age-related macular degeneration (nAMD ...

HealthDay News — For patients with diabetes, exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for incident neovascular age-related macular ...

GLP-1 RA use was linked to a 2.21-fold risk of developing neovascular age-related macular degeneration// (nAMD) * Only 0.2% ...

The management of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) continues to evolve through the constant refinement of treatment protocols and ...

Opens in a new tab or window New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Instead of receiving uncomfortable eye injections around once a month for a disease that can lead to blindness, patients may ...